

B S R & Co. LLP

Chartered Accountants

6th Floor, Tower- A, Plot No 07
Advant Navis Business Park
Sector- 142, Noida Expressway
Noida- 201305, UP, (India)

Telephone + 91 120 386 8000
Fax + 91 120 386 8999

Independent Auditor's Report

To the Members of Jubilant Pharma Holdings Inc. *(formerly known as Jubilant Life Sciences Holdings Inc.)*

Report on the Special Purpose Financial Statements

We have audited the accompanying Special Purpose Financial Statements of Jubilant Pharma Holdings Inc ("the Company"), which comprise Special Purpose Balance Sheet as at 31 March 2015, Special Purpose Statement of Profit and Loss and Special Purpose Cash Flow Statement and a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Special Purpose Financial Statements

Management is responsible for the preparation of these Special Purpose Financial Statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility includes design, implementation and maintenance of internal control relevant to the preparation and presentation of the Special Purpose Financial Statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made thereunder.

We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Special Purpose Financial Statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Special Purpose Financial Statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Special Purpose Financial Statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the Special Purpose Financial Statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on whether the Company has in place an adequate internal financial controls system over financial reporting and the operating effectiveness of such controls. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the Special Purpose Financial Statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Special Purpose Financial Statements.

Opinion

In our opinion and to the best of our information and according to the explanations given to us, the Special Purpose Financial Statements give the information required, as applicable in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India:

(a) in the case of the Special Purpose Balance Sheet, of the state of affairs of the Company as at 31 March 2015;

(b) in the case of the Special Purpose Statement of Profit and Loss, of the loss for the year ended on that date; and

(c) in the case of the Special Purpose Cash Flow Statement, of the cash flows for the year ended on that date.


Restriction of use

This audit report has been prepared at the request of the management of the Company solely for the purpose of submission to the Reserve Bank of India and should not be distributed, quoted or referred to, in whole or in part, to any party, without our prior written consent.

For B S R & Co. LLP

Chartered Accountants

ICAI Firm Registration Number: 101248W/W-100022



Pravin Tulsyan

Partner

Membership Number: 108044

Place: Noida

Date: 12 May 2015

Jubilant Pharma Holdings Inc. (formerly Jubilant Life Sciences Holdings Inc.)
Special Purpose Balance Sheet as at 31 March 2015

	Note	As at 31 March 2015		As at 31 March 2014	
		USD	Rs. '000	USD	Rs. '000
EQUITY AND LIABILITIES					
Shareholders' funds					
Share capital	3	213,486,975	9,466,116	213,486,975	9,466,116
Reserves and surplus	4	(5,327,266)	3,543,867	(46,245,667)	553,311
		208,159,709	13,009,983	167,241,308	10,019,427
Current liabilities					
Short-term borrowings	5	37,750,000	2,359,375	22,450,000	1,344,980
Trade payables	6	46,460	2,904	68,602	4,110
Other current liabilities	7	1,372,089	85,756	187,203	11,215
		39,168,549	2,448,035	22,705,805	1,360,305
	Total	247,328,258	15,458,018	189,947,113	11,379,732
ASSETS					
Non-current assets					
Non-current investments	8	177,443,845	11,090,242	144,243,075	8,641,603
Long-term loans and advances	9	544,623	34,039	-	-
		177,988,468	11,124,281	144,243,075	8,641,603
Current assets					
Cash and bank balances	10	6,865,913	429,120	6,996,819	419,179
Short-term loans and advances	11	62,473,877	3,904,617	38,707,219	2,318,950
		69,339,790	4,333,737	45,704,038	2,738,129
	Total	247,328,258	15,458,018	189,947,113	11,379,732

Significant accounting policies

2

The notes referred to above form an integral part of the special purpose financial statements

As per our report of even date attached

For B S R & Co. LLP
Chartered Accountants
ICAI Firm registration number: 101248W/W-100022


Pravin Tulsyan
Partner
Membership No.: 108044

Place: Noida, India
Date: 12 May 2015

For and on behalf of Board of Directors of
Jubilant Pharma Holdings Inc.


Paresh Gupta
Director
DIN : 5133745

Place: Montreal, Canada
Date: 10 May 2015

Jubilant Pharma Holdings Inc. (formerly Jubilant Life Sciences Holdings Inc.)
Special Purpose Statement of Profit and Loss for the year ended 31 March 2015

	Note	For the year ended 31 March 2015		For the year ended 31 March 2014	
		USD	Rs. '000	USD	Rs. '000
REVENUE					
Other operating income	12	16,351	999	4,026,323	237,424
Total revenue		16,351	999	4,026,323	237,424
EXPENSES					
Employee benefits expenses	13	335,119	20,894	-	-
Finance costs	14	1,163,682	71,252	187,203	11,534
Other expenses	15	210,104	12,984	207,534	12,604
Total expenses		1,708,905	105,130	394,737	24,138
(Loss) / Profit before exceptional items and tax		(1,692,554)	(104,131)	3,631,586	213,286
Exceptional items	16	1,500,000	91,725	3,960,000	244,530
Loss before tax		(3,192,554)	(195,856)	(328,414)	(31,244)
Tax expenses:					
- Current tax		2,000	122	-	-
- Deferred tax credit		(591,776)	(37,405)	(402,308)	(24,753)
		(589,776)	(37,283)	(402,308)	(24,753)
(Loss) / Profit for the year		(2,602,778)	(158,573)	73,894	(6,491)
Basic earnings per share	20	(2,343)	(143)	67	(6)
Diluted earnings per share	20	(2,343)	(143)	67	(6)


Significant accounting policies

2

The notes referred to above form an integral part of the special purpose financial statements

As per our report of even date attached


For B S R & Co. LLP
Chartered Accountants
ICAI Firm registration number: 101248W/W-100022



Pravin Tulsyan
Partner
Membership No.: 108044

Place: Noida, India
Date: 12 May 2015

For and on behalf of Board of Directors of
Jubilant Pharma Holdings Inc.



Paresh Gupta
Director
DIN : 5133745

Place: Montreal, Canada
Date: 10 May 2015

Jubilant Pharma Holdings Inc. (formerly Jubilant Life Sciences Holdings Inc.)
Special Purpose Cash Flow Statement for the year ended 31 March 2015


	For the year ended 31 March 2015		For the year ended 31 March 2014	
	USD	Rs. '000	USD	Rs. '000
A. Cash flows from operating activities				
Loss before tax	(3,192,554)	(195,856)	(328,414)	(31,244)
Adjustments:				
Finance costs	1,163,682	71,252	187,203	11,534
Provision for diminution in the value of investment	1,500,000	91,725	3,960,000	244,530
Provision no longer required written back	-	-	(21,875)	(1,351)
Interest income	(16,351)	(999)	-	-
	2,647,331	161,978	4,125,328	254,713
Operating (loss) / profit before working capital changes	(545,223)	(33,878)	3,796,914	223,469
Increase in trade and other receivables	(23,759,480)	(1,481,404)	(9,732,251)	(587,925)
Increase in investments	(2,440,100)	(152,140)	(3,080,000)	(186,063)
Increase in trade and other payable	12,439,393	775,596	8,691,128	525,031
Cash used in operations	(14,305,410)	(891,826)	(324,209)	(25,487)
Income tax paid (net of refund)	(135,403)	(8,280)	(8,495,849)	(513,234)
Interest received	16,351	999	-	-
Net cash used in operating activities	(14,424,462)	(899,107)	(8,820,058)	(538,721)
B. Cash flows from financing activities				
Loan from holding company - Jubilant Pharma Limited, net	-	-	1,750,000	105,718
Loan from ultimate holding company - Jubilant Life Sciences Limited	13,000,000	794,950	8,700,000	525,567
Repayment of loan to ultimate holding company - Jubilant Life Sciences Limited	(21,700,000)	(1,326,955)	-	-
Loan from fellow subsidiary - Jubilant Draximage Inc.	-	-	3,650,000	220,497
Loan from fellow subsidiary - Jubilant Cadista Pharmaceuticals Inc.	24,000,000	1,467,600	-	-
Dividend paid (including dividend distribution tax)	-	-	(50,000)	(3,087)
Finance cost paid	(1,006,444)	(61,544)	-	-
Net cash generated from financing activities	14,293,556	874,051	14,050,000	848,695
C. Foreign currency translation difference	-	34,997	-	13,281
Net (Decrease) / Increase in cash and cash equivalents (A+B+C)	(130,906)	9,941	5,229,942	323,255
Add: cash and cash equivalents at the beginning of year	6,996,819	419,179	1,766,877	95,924
Cash and cash equivalents at the close of the year	6,865,913	429,120	6,996,819	419,179

Note:

Cash Flow Statement has been prepared under the indirect method as set out in the Accounting Standard 3 (AS-3)-" Cash Flow Statements".

As per our report of even date attached


For BSR & Co. LLP
Chartered Accountants
ICAI Firm registration number: 101248W/W-100022



Pravin Tulsyan
Partner
Membership No.: 108044

Place: Noida, India
Date: 12 May 2015

For and on behalf of Board of Directors of
Jubilant Pharma Holdings Inc.



Paresh Gupta
Director
DIN : 5133745

Place: Montreal, Canada
Date: 10 May 2015

Jubilant Pharma Holdings Inc. (formerly Jubilant Life Sciences Holdings Inc.)
Notes to the special purpose financial statements for the year ended 31 March 2015

1. Corporate Information

Jubilant Pharma Holdings Inc. (formerly Jubilant Life Sciences Holdings Inc.) (the Company) was incorporated in United States of America under the local laws of Delaware in October 2005. The Company is a subsidiary of Jubilant Pharma Limited, Singapore (formerly Jubilant Pharma Pte. Limited), which holds 82% stake in the Company, balance stake of 18% is held by Jubilant Generics Limited, India which is transferred from Jubilant Life Sciences Limited, India, the ultimate holding company, during the year. The primary activities of the Company are of making investment.

2. Significant accounting policies

A. Basis of preparation and presentation of special purpose financial statements

The accounts of the Company are prepared under the historical cost convention on the accrual basis of accounting in accordance with the accounting principles generally accepted in India ("GAAP") and comply with the Accounting Standards specified under section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014 and pronouncements of the Institute of Chartered Accountants of India, to the extent applicable.

These special purpose financial statements have been prepared solely for the purpose of submission to the Reserve Bank of India.

The special purpose financial statements are presented in Indian rupees rounded off to the nearest thousand. The functional currency of the Company is United States Dollar (USD).

B. Use of estimates

The preparation of special purpose financial statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the application of accounting policies and reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of financial statements and the results of operations during the reporting periods. Management believes that the estimates used in the preparation of the financial statements are prudent and reasonable. Actual results could vary from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Appropriate changes in estimates are made as the management becomes aware of the changes in circumstances surrounding the estimates. Any revision to accounting estimates is recognised prospectively in current and future periods. Effect of material changes is disclosed in the notes to the financial statements.

C. Current and non-current classification

All assets and liabilities are classified as current or non-current as per the Company's normal operating cycle and other criteria in accordance with schedule III to the Companies Act, 2013 set out below:

Jubilant Pharma Holdings Inc. (formerly Jubilant Life Sciences Holdings Inc.)
Notes to the special purpose financial statements for the year ended 31 March 2015

Assets

An asset is classified as current when it satisfies any of the following criteria:

- a. it is expected to be realised in, or is intended for sale or consumption in, the Company's normal operating cycle;
- b. it is held primarily for the purpose of being traded;
- c. it is expected to be realised within 12 months after the reporting date; or
- d. it is cash or cash equivalent unless it is restricted from being exchanged or used to settle a liability for at least 12 months after the reporting date.

Current assets include the current portion of non-current financial assets.

All other assets are classified as non-current.

Liabilities

A liability is classified as current when it satisfies any of the following criteria:

- a. it is expected to be settled in the Company's normal operating cycle;
- b. it is held primarily for the purpose of being traded;
- c. it is due to be settled within 12 months after the reporting date; or
- d. the Company does not have an unconditional right to defer settlement of the liability for at least 12 months after the reporting date. Terms of a liability that could, at the option of the counterparty, result in its settlement by the issue of equity instruments do not affect its classification.

Current liabilities include current portion of non-current financial liabilities.

All other liabilities are classified as non-current.

Operating cycle

Operating cycle is the time between the acquisition of assets for processing and their realisation in cash or cash equivalents.

Based on the nature of products and the time between the acquisition of assets for processing and their realisation in cash and cash equivalents, the Company has ascertained its operating cycle as 12 months for the purpose of current and non-current classification of assets and liabilities.

D. Investments

Investments that are readily realisable and are intended to be held for not more than one year from the date, on which such investments are made, are classified as current investments. All other investments are classified as long-term investments. However, that part of long-term investments which is expected to be realised within 12 months after the reporting date is also presented under 'current assets' as "current portion of long-term investments" in consonance with the current/non-current classification scheme of Schedule III of Companies Act, 2013.

Current investments are carried at cost or fair value, whichever is lower. Long-term investments are carried at cost. However, provision for diminution is made to recognise a decline, other than temporary, in the value of the investments, such reduction being determined and made for each investment individually.

E. Income taxes

Tax expense for the period, comprising current tax and deferred tax, are included in the determination of the net profit or loss for the period.

Current tax

Current tax expense is based on the local tax laws in United States of America and is measured at the amount expected to be paid to/ (recovered from) the taxation authorities, using the applicable tax rates and tax laws.

Deferred tax

Deferred tax charge or credit reflects the tax effects of timing differences between accounting income and taxable income for the current year and reversal of timing differences for earlier years. The deferred tax charge or credit and the corresponding deferred tax liabilities or assets are recognised using the tax rates that have been enacted or substantively enacted by the Balance Sheet date. Deferred tax assets are recognised only to the extent there is reasonable certainty that the assets can be realised in future; however, where there is unabsorbed depreciation or carry forward of losses, deferred tax assets are recognised only if there is a virtual certainty of realization of such assets. Deferred tax assets are reviewed at each Balance Sheet date and are written-down or written-up to reflect the amount that is reasonably/ virtually certain (as the case may be) to be realised.

Also refer note 17.

F. Foreign Currency Conversions/ Translations

Foreign currency transactions are recorded in the reporting currency, by applying to the foreign currency amount the exchange rate between the reporting currency and the foreign currency on/ or closely approximating to the date of the transaction. All monetary assets and liabilities in foreign currency are restated at the end of accounting period. Exchange differences arising on the settlement of monetary items or on reporting of such monetary items of the Company at rates different from those at which they were initially recorded during the year, or reported in previous financial statements, are recognized as income or expenses in the year in which they arise.

For presentation in Indian rupee (INR), the special purpose financial statements are translated into INR as follows:-

- Share capital and opening reserves and surplus are carried at historical cost.
 - All assets and liabilities, both monetary and non-monetary, (excluding share capital, opening reserves and surplus) are translated using closing rates at Balance Sheet date.
 - Profit and Loss items are translated at the respective quarterly average rates or the exchange rate that approximates the actual exchange rate on date of specific transaction.
 - The resulting net exchange difference is credited or debited to the foreign currency translation reserve.
-

G. Provisions, contingent liabilities and contingent assets

The Company recognises a provision when there is a present obligation as a result of a past event that probably requires an outflow of resources and a reliable estimate can be made of the amount of the obligation. Contingent liabilities are disclosed in respect of possible obligations that may arise from past events but their existence is confirmed by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the Company. Contingent assets are neither recognised nor disclosed in the special purpose financial statements. However, contingent assets are assessed continually and if it is virtually certain that an inflow of economic benefits will arise, the asset and related income are recognised in the period in which the change occurs.

H. Employee benefits

Contributions to defined contribution plans are charged to special purpose statement of profit and loss in the period in which they accrue.

I. Dividend income

Dividend income is recognised when the right to receive payment is established.

J. Interest income

Interest income is recognised on a time proportion basis taking into account the amount outstanding and the interest rate applicable.

K. Earnings per share

The basic earnings per share is calculated by dividing the net profit after tax for the year by the weighted average number of equity shares outstanding during the year. For the purpose of calculating diluted earnings per share, net profit after tax during the year and the weighted average number of shares outstanding during the year are adjusted for the effect of all dilutive potential equity shares. The dilutive potential equity shares are deemed converted as of the beginning of the year unless they have been issued at a later date. The dilutive potential equity shares are adjusted for the proceeds receivable had the shares been actually issued at fair value (i.e. average market value of the outstanding shares). Anti-dilutive effect of any potential equity shares is ignored in the calculation of earnings per share.

Jubilant Pharma Holdings Inc. (formerly Jubilant Life Sciences Holdings Inc.)
Notes to the special purpose financial statements for the year ended 31 March 2015

	As at 31 March 2015		As at 31 March 2014	
	USD	Rs. '000	USD	Rs. '000
3. SHARE CAPITAL				
Authorised				
Equity share capital	-	-	-	-
3,000 shares at zero par value (Previous year - 3000 shares at zero par value)	-	-	-	-
Issued, Subscribed and Paid up				
Equity share capital	213,486,975	9,466,116	213,486,975	9,466,116
200 shares of class A and 911 shares of class B common stock (Previous year 200 shares of class A and 911 shares of class B common stock)				
	213,486,975	9,466,116	213,486,975	9,466,116

3.1) The Company has two classes of stock, Class A common stock and Class B common stock. The total number of shares of all classes of stock which the Company is authorized to issue is 3,000 shares of zero par value. Of the total authorized shares, 1,500 shares shall be authorized to be issued as Class A common stock, at zero par value and 1,500 shares shall be authorized to be issued as Class B common stock, at zero par value.

The voting powers for the shareholder shall be vested equally in the holders of Class A common stock and Class B common stock, with each share of stock entitled to one vote. No rights to class voting shall exist for either class of common stock.

The holder of Class A common stock shall have all rights and preferences with respect to dividend declared by the Company, except to the extent that the Board of Directors makes a special dividend declaration to the holders of Class B common stock.

Except for the foregoing dividend preference rights, Class A common stock and Class B common stock shall have equal rights with respect to (i) voting; (ii) liquidating distributions made to the shareholders; (iii) any distribution of the Company assets to its shareholders; and (iv) any other shareholder rights and privileges.

3.2) In the event of liquidation of the Company, the holders of equity shares shall be entitled to receive all of the remaining assets of the Company, after distribution of all preferential amounts, if any. Such amounts will be in proportion to the number of equity shares held by the stockholders.

3.3) The details of shares held by holding/ultimate holding company:

Name of the shareholders	As at 31 March 2015		As at 31 March 2014	
	No. of shares	USD	No. of shares	USD
Jubilant Pharma Limited, Singapore (formerly Jubilant Pharma Pte Limited, Singapore) - the holding company Class B common stock at zero par value	911	176,286,975	911	176,286,975
Jubilant Life Sciences Limited - ultimate holding company Class A common stock at zero par value	-	-	200	37,200,000
Jubilant Generics Limited, India Class A common stock at zero par value	200	37,200,000	-	-

3.4) The details of shareholders holding more than 5% shares is set out below:

Name of the shareholders	As at 31 March 2015		As at 31 March 2014	
	No. of shares	% holding	No. of shares	% holding
Jubilant Pharma Limited, Singapore (formerly Jubilant Pharma Pte Limited, Singapore) - the holding company	911	82.00%	911	82.00%
Jubilant Life Sciences Limited - ultimate holding company	-	-	200	18.00%
Jubilant Generics Limited, India	200	18.00%	-	-

3.5) The reconciliation of the number of shares outstanding is set out below:

Particulars	As at 31 March 2015		As at 31 March 2014	
	No. of shares	Rs. '000	No. of shares	Rs. '000
At the commencement and at the end of the year	1,111	9,466,116	1,111	9,466,116

Jubilant Pharma Holdings Inc. (formerly Jubilant Life Sciences Holdings Inc.)
Notes to the special purpose financial statements for the year ended 31 March 2015

	As at 31 March 2015		As at 31 March 2014	
	USD	Rs. '000	USD	Rs. '000
4. RESERVES AND SURPLUS				
Foreign currency translation reserve				
At the commencement of the year	-	2,656,479	-	1,703,287
Additions during the year	-	487,809	-	953,192
At the end of the year	-	3,144,288	-	2,656,479
Capital reserve				
At the commencement of the year	21,025,000	1,138,972	-	-
Additions during the year (refer note 17 and 21)	43,521,179	2,661,320	21,025,000	1,138,972
At the end of the year	64,546,179	3,800,292	21,025,000	1,138,972
Deficit				
At the commencement of the year	(67,270,667)	(3,242,140)	(68,208,269)	(3,282,222)
Net (Loss)/Profit after tax transferred from statement of profit and loss	(2,602,778)	(158,573)	73,894	(6,491)
Adjustments (refer note 17)	-	-	913,708	49,660
	(69,873,445)	(3,400,713)	(67,220,667)	(3,239,053)
Less: Appropriations				
Dividend on equity shares*	-	-	50,000	3,087
* Dividend paid to holding company Jubilant Pharma Limited				
At the end of the year	(69,873,445)	(3,400,713)	(67,270,667)	(3,242,140)
	(5,327,266)	3,543,867	(46,245,667)	553,311
5. SHORT TERM BORROWINGS				
Loans from related parties (unsecured)(refer note 19)	37,750,000	2,359,375	22,450,000	1,344,980
	37,750,000	2,359,375	22,450,000	1,344,980
Above includes:				
i) Interest free loan from Jubilant Pharma Limited	10,100,000	631,250	10,100,000	605,092
ii) Loan from Jubilant Life Sciences Limited carried interest @ 5% p.a.	-	-	8,700,000	521,217
iii) Loan from Jubilant DraxImage Inc. carries interest @ 4% p.a.	3,650,000	228,125	3,650,000	218,672
iv) Loan from Jubilant Cadista Pharmaceuticals Inc. carries interest @ 4% p.a.	24,000,000	1,500,000	-	-
6. TRADE PAYABLES				
Trade payable - others	46,460	2,904	68,602	4,110
	46,460	2,904	68,602	4,110
7. OTHER CURRENT LIABILITIES				
Interest accrued and due on borrowings (refer note 19)	344,441	21,528	187,203	11,215
Employee benefits	33,025	2,064	-	-
Due to related party (refer note 19)	994,623	62,164	-	-
	1,372,089	85,756	187,203	11,215

Jubilant Pharma Holdings Inc. (formerly Jubilant Life Sciences Holdings Inc.)
Notes to the special purpose financial statements for the year ended 31 March 2015

	As at 31 March 2015		As at 31 March 2014	
	USD	Rs. '000	USD	Rs. '000
8. NON-CURRENT INVESTMENTS				
(At Cost)				
Trade investments				
Investment in equity instruments (fully paid up equity shares)				
Jubilant Clinsys Inc. 39,578,978 shares (previous year 38,650,016 shares) of zero par value	71,354,324	4,459,645	69,854,324	4,184,973
HSL Holdings Inc. 1,583 shares (previous year 1,582 shares) @ USD 0.01 par value	110,785,000	6,924,064	110,770,000	6,636,231
Jubilant Generics Inc. (formerly Generic Pharmaceuticals Holdings Inc.)* Nil shares (previous year 210 shares) @ USD 0.01 par value	-	-	33,473,075	2,005,372
Cadista Holdings Inc. * 117,797,190 shares (previous year nil shares) @ USD 0.001 par value	66,658,745	4,166,172	-	-
Jubilant Pharma Trading Inc. 101 shares (previous year nil shares) of zero par value	100	6	-	-
	248,798,169 (71,354,324)	15,549,887 (4,459,645)	214,097,399 (69,854,324)	12,826,576 (4,184,973)
	177,443,845	11,090,242	144,243,075	8,641,603
*refer note 21				
9. LONG TERM LOANS AND ADVANCES				
Advance tax	544,623	34,039	-	-
	544,623	34,039	-	-
10. CASH AND BANK BALANCES				
Cash and cash equivalents				
Balances with banks:				
- On current accounts	6,865,913	429,120	6,996,819	419,179
	6,865,913	429,120	6,996,819	419,179
11. SHORT-TERM LOANS AND ADVANCES				
Loans to related party (unsecured, considered good) (refer note 19)	61,816,000	3,863,500	38,050,000	2,279,576
Advance recoverable in cash and kind				
- From related parties (refer note 19)	657,877	41,117	657,219	39,374
	62,473,877	3,904,617	38,707,219	2,318,950

Jubilant Pharma Holdings Inc. (formerly Jubilant Life Sciences Holdings Inc.)
Notes to the special purpose financial statements for the year ended 31 March 2015

	For the year ended 31 March 2015		For the year ended 31 March 2014	
	USD	Rs. '000	USD	Rs. '000
12. OTHER OPERATING INCOME				
Interest income	16,351	999	4,448	273
Dividend income from investments (non-trade)	-	-	4,000,000	235,800
Provision no longer written back	-	-	21,875	1,351
	16,351	999	4,026,323	237,424
13. EMPLOYEE BENEFITS EXPENSES				
Salaries, wages and allowances	318,192	19,839	-	-
Contribution to social security schemes	12,528	781	-	-
Staff welfare expenses	4,399	274	-	-
	335,119	20,894	-	-
14. FINANCE COSTS				
Interest expense	1,163,682	71,252	187,203	11,534
	1,163,682	71,252	187,203	11,534
15. OTHER EXPENSES				
Rates and taxes	125	8	44	3
Auditors remuneration	6,318	388	5,000	305
Legal, professional and consultancy charges	142,015	8,745	201,727	12,250
Bank charges	2,642	164	763	46
Travelling and other incidental expenses	56,730	3,537	-	-
Communication expenses	442	28	-	-
Advertisement, publicity and sales promotion	550	34	-	-
Miscellaneous expenses	1,282	80	-	-
	210,104	12,984	207,534	12,604
16. EXCEPTIONAL ITEMS				
Diminution in value of investment (refer note 8)	1,500,000	91,725	3,960,000	244,530
	1,500,000	91,725	3,960,000	244,530

Jubilant Pharma Holdings Inc. (formerly Jubilant Life Sciences Holdings Inc.)
Notes to the special purpose financial statements for the year ended 31 March 2015
All amounts in USD (Rs. '000)

17. The Company being a holding company for various United States of America (USA)/ Canada based direct/ indirect subsidiaries/ majority owned entities and therefore files federal tax return and state tax return (as applicable) on a consolidated basis. Current and deferred income taxes are recognised by each entity within the group, regardless of which entity has the legal liability for settlement or recovery of the tax. Current and deferred tax amounts for each entity within the tax group are determined and recognised under a systematic, rational and consistent method.

The Company has a tax sharing arrangement with Cadista Holdings Inc. (Cadista), a fellow subsidiary which was effective from October 1, 2011. The Agreement sets forth, among other things, each of the Company's and Cadista obligations in connection with filing consolidated federal, state and foreign tax returns. The agreement provides that current income tax (benefit) is computed on a separate return basis and Cadista shall make payments (or receive reimbursement) to or from the Company to the extent its income (losses and other credits) contribute to (reduce) the consolidated income tax expense. No such agreement exists with any other group entity.

In view of the tax sharing agreement, the Company has received USD 11,985,688 (Rs. 732,925) (Previous year USD 16,196,000 (Rs. 978,400)) from Cadista as current federal income tax as computed on a separate return basis for financial year 2014-15 which is recorded through capital reserve.

The amount of excess tax computed on consolidated tax return basis (federal and state) as reduced by the amount collected under aforesaid tax sharing arrangement over the current tax computed for the Company assuming as if it was filing a separate tax return instead of a consolidated tax return has been recognized as debit/ credit to capital reserve.

In assessing virtual certainty for the realizability of deferred tax asset, the assessment is performed on consolidated group basis and the corresponding adjustment is also recorded through capital reserve.

Further, during the financial year 2012-13, the consolidated state tax paid by the Company amounting to USD 913,708 (Rs. 49,660) was recognised as current tax expense, the same has been adjusted to deficit with a corresponding effect to capital reserve in the previous year.

18. Deferred Tax Assets and Liabilities are attributable to the following items:

Particulars	As at 31 March 2015		As at 31 March 2014	
	USD	Rs. '000	USD	Rs. '000
Deferred Tax Assets				
Accumulated Losses as per Tax Laws of the country in which the company is taxed	2,517,843	157,365	1,926,067	115,391
Less: Allocated to capital reserve	(2,517,843)	(157,365)	(1,926,067)	(115,391)
Deferred Tax Assets (Net)	-	-	-	-

Jubilant Pharma Holdings Inc. (formerly Jubilant Life Sciences Holdings Inc.)
Notes to the special purpose financial statements for the year ended 31 March 2015
All amounts in USD (Rs. '000)

19. Related Party Disclosures

Related Parties of the Company

Ultimate Holding Company

Jubilant Life Sciences Limited, India

Holding Company

Jubilant Pharma Limited, Singapore (formerly Jubilant Pharma Pte. Limited, Singapore)

Subsidiaries including Step-down subsidiaries

HSL Holdings Inc.

Jubilant HollisterStier LLC

Jubilant Clinsys Inc.

Cadista Holdings Inc.

Jubilant Generics Inc. (formerly Generics Pharmaceuticals Inc.) (till December 22, 2014)

Jubilant HollisterStier Inc.

Draxis Pharma LLC

Jubilant Cadista Pharmaceuticals Inc.

Fellow subsidiary

Jubilant DraxImage Inc.

Jubilant Life Sciences (USA) Inc.

Jubilant Generics Limited, India

The Company has entered into transactions with the following related parties:

Particulars	31 March 2015		31 March 2014	
	USD	Rs. '000	USD	Rs. '000
Ultimate Holding Company – Jubilant Life Sciences Limited, India				
Loan received during the year	13,000,000	794,950	8,700,000	525,567
Loan repaid during the year	(21,700,000)	(1,326,955)	-	-
Interest charged during the year	907,654	55,503	98,792	6,087
Balance outstanding for interest payable	-	-	(98,792)	(5,918)
Balance outstanding at the year end	-	-	(8,700,000)	(521,217)
Holding Company – Jubilant Pharma Limited, Singapore				
Loan received during the year	-	-	5,800,000	350,378
Loan repaid during the year	-	-	4,050,000	244,661
Balance outstanding at the year end	(10,100,000)	(631,250)	(10,100,000)	(605,091)

Jubilant Pharma Holdings Inc. (formerly Jubilant Life Sciences Holdings Inc.)

Notes to the special purpose financial statements for the year ended 31 March 2015

All amounts in USD (Rs. '000)

Particulars	31 March 2015		31 March 2014	
	USD	Rs. '000	USD	Rs. '000
Subsidiary Companies				
Jubilant Clinsys Inc.				
Investment in equity share capital	1,500,000	91,725	3,060,000	184,855
Expenses reimbursed (Including taxes)	295,708	18,083	8,521,894	514,808
Balance outstanding at the year end	(520)	(33)	-	-
Jubilant Generics Inc.				
Investment in equity share capital	925,000	56,564	20,000	1,208
Balance outstanding at the year end	-	-	-	-
HSL Holdings Inc.				
Interest free Loan given during the year	23,766,000	1,453,291	17,450,000	1,054,155
Balance outstanding at the year end	61,816,000	3,863,500	38,050,000	2,279,576
Jubilant HollisterStier LLC				
Expenses reimbursed	-	-	13,520	817
Balance outstanding at the year end	(13,520)	(845)	(13,520)	(810)
Jubilant Cadista Pharmaceuticals Inc.				
Income tax received as per tax sharing agreement	11,985,688	732,925	16,196,000	978,400
Advance received	450,000	27,517	-	-
Expenses reimbursed	933	57	-	-
Loan received during the year	24,000,000	1,467,600	-	-
Interest charged during the year	108,000	6,604	-	-
Balance outstanding for interest payable	(108,000)	(6,750)	-	-
Balance outstanding at the year end	(23,796,169)	(1,487,261)	654,764	39,227
Fellow Subsidiary				
Jubilant DraxImage Inc.				
Loan received during the year	-	-	3,650,000	220,497
Interest charged during the year	148,028	9,052	88,411	5,447
Tax expenses incurred	544,623	33,304	-	-
Balance outstanding for interest payable	(236,441)	(14,778)	(88,411)	(5,297)
Balance outstanding at the year end	(4,194,623)	(262,164)	(3,650,000)	(218,672)
Jubilant Life Sciences (USA) Inc.				
Expenses recharged	658	40	-	-
Balance outstanding at the year end	3,113	195	2,455	147

Jubilant Pharma Holdings Inc. (formerly Jubilant Life Sciences Holdings Inc.)
Notes to the special purpose financial statements for the year ended 31 March 2015
All amounts in USD (Rs. '000)

Particulars	31 March 2015		31 March 2014	
	USD	Rs. '000	USD	Rs. '000
Jubilant Generics Limited, India				
Expenses reimbursed	17,481	1,069	-	-
Balance outstanding at the year end	(17,481)	(1,093)	-	-

(Figures in brackets represent amount payable by the company).

20. Earnings per share (EPS)

	For the year ended 31 March 2015		For the year ended 31 March 2014	
	USD	Rs. '000	USD	Rs. '000
I. (Loss) /Profit for basic and diluted earnings per share (USD)	(2,602,778)	(158,573)	73,894	(6,491)
II. Weighted average number of equity shares	1,111	1,111	1,111	1,111
III. Earnings per share (USD)	(2,343)	(143)	67	(6)

21. On December 22, 2014, Jubilant Generics Inc. (JGI) a wholly owned subsidiary of the Company, acquired through tender offer process 17,018,378 equity shares held by the minority (representing approximately 82% of the minority not held by JGI) in Cadista Holdings Inc. (CHI) for USD 1.60 per share. JGI also completed a short form merger with and into CHI and as a result of the merger the remaining 3,735,228 shares belonging to minority were cancelled and converted into right to receive USD 1.60 per share in cash without interest, subject to appraisal law under the Delaware law. The consideration for this transaction is USD 33,205,770. As a result of above transaction, investment by the Company amounting to USD 34,398,075 (including investment made during the year USD 925,000) in JGI is set off against the investment held by JGI in CHI amounting to USD 66,658,745 and the balance amounting to USD 32,260,670 is adjusted in capital reserve. Pursuant to this transaction, CHI has become a step down wholly owned subsidiary of the Company.

22. Foreign currency exposure not hedged by derivative instrument

Unhedged foreign currency presented against USD, being the functional currency of the Company.

Details	Currency	31 March 2015	31 March 2014
		Amount in foreign currency	
Amount payable on account of expenses incurred	CAD	694,394	-


23. Prior period items for the year ended 31 March 2015 is USD 71,135 (Rs. 4,350) (previous year USD (234,234) (Rs. 14,150)).

Jubilant Pharma Holdings Inc. (formerly Jubilant Life Sciences Holdings Inc.)
Notes to the special purpose financial statements for the year ended 31 March 2015
All amounts in USD (Rs. '000)

24. In the opinion of the management, there are no reportable segments as envisaged by the Accounting Standard-17 – "Segment Reporting". Accordingly, no disclosure for segment reporting has been made in the financial statements.

As per our report of even date attached.


For B S R & Co. LLP
Chartered Accountants
ICAI Firm registration number: 101248W/W-100022



Pravin Tulsyan
Partner
Membership No.: 108044

Place: Noida, India
Date: 12 May 2015

For and on behalf of Board of Directors of
Jubilant Pharma Holdings Inc.



Paresh Gupta
Director
DIN : 5133745

Place: Montreal, Canada
Date: 10 May 2015